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Trachoma is the leading infectious cause
of blindness worldwide, and responsible for
the loss of an estimated 1.3 million
disability-adjusted life years, mainly in
sub-Saharan Africa [1]. Geographically,
trachoma is a greater public health risk in
dry, dusty, and hot settings, where poor,
rural communities suffer a disproportionate
burden of disease. Trachoma is caused by
infection with the bacterium Chlamydia
trachomatis, but the condition has a number
of clinical manifestations that are the
consequences of current or past infection
[2]. Prevalence of infection and clinical
signs of follicular conjunctivitis are highest
in children under 10 y of age. Recurrent
episodes of infection and associated inflam-
mation can cause scarring, visual impair-
ment, and potential blindness later in life.
In 1998, the World Health Organization
(WHO) established an international alliance
eliminate trachoma as a public health
problem by 2020, called the Alliance for
Global Elimination of Trachoma by the
year 2020 (GET2020). The goal of
GET2020 is to reduce the burden of
trachoma in any community to less than
one case of trachomatous trichiasis (TT) per
1,000 total population, and to less than 5%
prevalence of ‘‘trachomatous inflammation–
follicular’’ (TF) in children aged 1–9 y [3].
The strategy employed to reach thesetargets
is based on a combination of interventions
known as SAFE: Surgery to correct trichi-
asis, Antibiotics for C. trachomatis infection,
Facial cleanliness, and Environmental im-
provement to reduce transmission. In order
to allow time for programme implementa-
tion and impact by 2020, it will be necessary
to scale up to full SAFE implementation in
all endemic districts by 2015. An essential
component of this effort is producing up-to-
date and accessible maps of the distribution
of trachoma for advocacy, planning, and
operational research purposes.
Why Are Updated Maps
Important for Trachoma and Its
Control?
No one would question the importance
of a geographical understanding of tra-
choma in the initial planning of national
control programmes. However, there are
important reasons why we need to continue
to update our geographical understanding
of trachoma as the program is implement-
ed, and why maps should be made publicly
available. First, and the importance of this
reason should not be underestimated, maps
play a vital advocacy role, showcasing the
achievements of control efforts to date and
showing where further control resources
are still required. This advocacy will help
leverage continual funding.
Second, updated maps can help refine
ongoing controleffortsbyidentifyingwhere
control has been successful in reducing the
burden of trachoma and where it has been
less so, indicating where efforts need to be
intensified in order to achieve the goals of
GET2020. Numerous survey data have
been collected since the implementation of
national control programmes in many
endemic countries [4,5], and inclusion of
these data into updated maps provides a
better information base for the evaluation
of disease distributions and future planning
of control efforts. It is true that in some
countries, the most recent information may
already be available to control managers,
but this may not always be the case, and
both the requisite time and technical
capacity to quickly update maps are often
lacking. In Southern Sudan, for example, a
recent mapping exercise collated all avail-
able trachoma data into a single database
for the first time and provided valuable
information for planning control [6]. Up-
dated maps can help identify where
epidemiological data are still absent and
highlight where additional surveys are
required to define future control needs.
Furthermore, maps allow programme
managers to more fully explore patterns
of endemicity on the borders of their
programme area, which may prompt
further survey work and coordination of
control efforts within populations that are
mobile across those borders.
Third, updated trachoma maps are
essential for deriving reliable estimates of
the disease burden of trachoma. A recent
review by Burton and Mabey [7] high-
lighted the unreliability of current global
prevalence estimates, which is partly due
to extrapolation of limited estimates across
countries and regions. Collation, mapping,
and analysis of data collected through
cluster population sampling [3] can help
generate more precise estimates of the
burden of trachoma within a country, as
well as allow a better evaluation of the
geographical overlap with other neglected
tropical diseases. This evaluation can take
advantage of other ongoing efforts to map
the global distribution of schistosomiasis
and soil-transmitted helminth infections
[8,9].
Finally, high-resolution mapping of
trachoma has a number of operational
research applications, as indicated below.
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In 2005, the International Centre for
Eye Health at the London School of
Hygiene and Tropical Medicine, in col-
laboration with the Programme for the
Prevention of Blindness and Deafness at
the WHO, developed a first global atlas of
trachoma using data consolidated at the
district level (defined as the normal
administrative level for health care man-
agement) [10]. A new collaboration be-
tween the International Trachoma Initia-
tive and the London School of Hygiene
and Tropical Medicine is updating this
atlas to reflect the changing burden of
trachoma, while also allowing for chang-
ing administrative boundaries and provid-
ing a flexible approach in calculating
district-level estimates of disease burden.
The aim of the current mapping project is
two-fold: (i) to provide district-level prev-
alence maps of the current distribution of
trachoma for all implementation partners,
and (ii) to collate and geolocate disaggre-
gated estimates of trachoma by survey
cluster for operational research purposes.
Updated district-level maps were made
publicly available in early 2011 on an open-
access Web site (http://www.trachomaatlas.
org/). We are continuing to collate data and
update maps in real time whenever further
data are received. Such an open-access
information resource complements recent
efforts to develop a Global Atlas of Helminth
Infection (http://www.thiswormyworld.org/)
[8] launched in 2010.
What Data Should Be Included
in the Trachoma Atlas?
The burden of trachoma is usually
assessed using one of three survey meth-
odologies: population-based prevalence
surveys (PBPSs), acceptance sampling
trachoma rapid assessment (ASTRA), or
trachoma rapid assessment (TRA). While
each survey methodology has its relative
benefits and limitations [11], PBPSs re-
main the gold standard for estimating
prevalence at the district level. However,
ASTRA and TRA can also contribute to
our understanding of the global distribu-
tion of trachoma. In particular, TRAs
provide information on whether trachoma
is present or absent in the most vulnerable
populations within a district or communi-
ty. ASTRA employs an adaptation of lot
quality assurance sampling, which can
give valid cluster-level prevalence esti-
mates with varying precision and, if nested
within an area-sampling framework, may
provide finer spatial resolution than other
methods [12]. To date, lot quality assur-
ance sampling methodologies have been
shown to provide a rapid, valid, and cost-
effective approach for identifying commu-
nities requiring interventions for schisto-
somiasis and other neglected tropical
diseases [13], and are being investigated
for use in assessing the burden of tracho-
ma. It will be important to establish to
what extent trachoma data collected using
these differing surveys methods can be
integrated into a single cartographic plat-
form, and this is an important research
priority.
Epidemiological data on trachoma are
typically based on diagnosis using ocular
examination, predominantly using the
1987 WHO simplified grading system.
This system was developed for the simple
and reliable grading of trachoma clinical
signs by non-specialist health personnel, as
ophthalmologists are in short supply in the
resource-poor settings in which trachoma
is found [14]. Laboratory methods, such as
polymerase chain reaction (PCR)–based
assays, provide information on presence or
absence of C. trachomatis infection [14], but
currently remain largely confined to re-
search studies because of their high cost.
In the future, however, alternative rapid
diagnostic tests for trachoma may be
available for mapping trachoma.
To assemble the updated global atlas
of trachoma available at http://www.
trachomaatlas.org/, we used a combina-
tion of electronic literature searches,
manual searches of private journal collec-
tions, and contact with a network of
trachoma researchers and programme
managers. Identified studies are subject
to a strict review process, in which
representative prevalence estimates from
PBPSs and ASTRA sampling techniques
are included in the database. In keeping
with relevant control guidelines, the core
indicators represented in the atlas are TF
in children aged 1–9 y and TT in adults
over the age of 14 y. Despite our focus on
surveys that use standard methods and
indicators recommended by the WHO,
TRA surveys can be used to indicate the
presence or absence of disease where
PBPSs are lacking. Relevant content
included in the database is summarised
in Box 1. To avoid cluster-level data
being used as prevalence estimates for
communities, only district-level maps are
available on the Web site.
Why Include Cluster-Level Data
in the Atlas?
Trachoma is a focal disease, and
reduction in prevalence has been observed
to occur unevenly throughout a district
[12]. As overall transmission of C. tracho-
matis is reduced, the spatial heterogeneity of
infection is likely to increase. Higher
resolution mapping of trachoma will there-
fore help identify and target high-preva-
lence foci over different stages of control.
Fine-scale mapping of trachoma has two
important potential research applications.
First, it can inform the refinement of
mapping strategies, particularly in settings
Box 1. Database Content
Although preferred clinical indicators are TF in children aged 1–9 years and TT in
adults over 14 y, alternative indicators and age groups are recorded based on
availability. For each district and cluster, the following data are requested:
N Site name (district or village name) and type of location (district or village)
N Longitude and latitude of community or cluster (if available)
N Region and district in which the survey was done
N Survey methodology and population sampling
N Year of survey
N Active trachoma
# Clinical indicator (TF, TF/TI
a, or TI)
# Age range
# Number examined
# Number graded positive
N Trichiasis
# Age range
# Number examined
# Number graded positive for TT
aTI, trachomatous inflammation–intense.
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The ability of alternative survey designs to
accurately identify remaining disease foci
can be investigated using spatial analysis
and conditional simulation [15].
Second, it may be possible to generate
risk maps of trachoma based on environ-
mental and other spatial covariates. Tra-
choma has strong and consistent links with
poverty, the effects of which may influence
observed associations with climatic factors,
water availability, latrine access, and
standard of hygiene [16]. Other studies
have reported the risk of trachoma to vary
in relation to altitude, which may influ-
ence the density of flies and thus trans-
mission through these vectors [17,18].
Environmental and climatic data are
nowadays readily available through satel-
lite data, and integration of such data with
estimates of trachoma prevalence may
help predict the risk of trachoma in
unsampled locations. The potential of
spatial analysis of trachoma and risk
mapping has recently been demonstrated
for Southern Sudan [6].
Potential Limitations
An obvious limitation of our updated atlas
is the inherent variation in the quality and
availability of data between included studies.
Older surveys may not capture recent
reductions in trachoma due to improvements
in socioeconomic status, water and sanitation,
and hygienic behaviours. In addition, al-
though the WHO’s simplified grading system
has good inter- and intra-observer agree-
ment, other aspects of survey design may
limit the precision of reported prevalence
estimates, including the number of clusters
surveyed and the administrative unit for
which the survey was representative. Differ-
ences in sampling methodology, the clinical
indicator reported, and age groups surveyed
will also reduce comparability of data;
however, inclusion of this information in the
database will allow stratification of data and
possible calibration of data to enhance data
comparability. Finally, although there has
been an increase in available survey data in
Figure 1. Map of Nepal showing district-level prevalence estimates of TF in children aged 1–9 years. In the updated trachoma atlas,
district-level maps of each country, such as this one for Nepal, categorise prevalence according to WHO treatment thresholds, and include TRA
surveys to indicate the presence or absence of trachoma. The inset shows disaggregated cluster estimates based on the most recent PBPS data. This
map might be used to advocate for further support for PBPSs in areas where trachoma has been found by TRA surveys. An exploratory analysis of the
spatial structure of trachoma in Nepal using cluster data shows marked heterogeneity within districts, and a clear spatial structure that could be used
to generate interpolated maps and prioritize data collection in unsurveyed districts.
doi:10.1371/journal.pntd.0000973.g001
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information for much of Asia.
Future Applications and
Conclusion
The new trachoma atlas, which has
recently been made available on an open-
access Web site (http://www.trachomaatlas.
org/), provides an important resource for all
stakeholders involved in trachoma control.
For countries without national programmes
or in need of massive scale up, the atlas will
likely provide a tool to determine treatment
needs, enable more effective monitoring and
evaluation of ongoing control activities, and
help identify control needs through a gap
analysis. An example of the maps to be
produced is shown in Figure 1. The current
trachoma atlas initiative represents a re-
newed effort to update the global distribu-
tion of endemic trachoma, and to both
provide maps for all implementation part-
ners and consolidate disaggregated data for
future detailed mapping and operational
research. The trachoma atlas may be used
alongside maps of the geographical imple-
mentation of SAFE interventions at sub-
national levels, recently made available by
the International Coalition for Trachoma
Control (http://www.trachomacoalition.
org/). It is hoped that these atlases will be
a valuable resource accessible to all stake-
holders, but their utility will depend on a
collaborative effort by the international
trachoma community to ensure that the
most up-to-date data are included and that
the developed maps are effectively used.
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